CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway
Related Experiment Video
Updated: Jun 2, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Jianfeng Zheng1, Rongquan Fu, Jing Li
1Department of Clinical Laboratory, the Second Affiliated hospital of Nanchang University, Nanchang 330006, China.
Objective:
To explore the potential role of CpG motif-containing oligonucleotides (CpG-ODN) in modulating the expression of FasL in HepG2 and Fas in Jurkat cells in vitro, and to examine the effect of CpG-ODN treatment on the HepG2 cells-mediated Jurkat cell apoptosis in vitro.
Methods:
The expressions of FasL in HepG2 and Fas in Jurkat cells were examined by real time PCR and flow cytometry (FCM). HepG2 and Jurkat cells were co-cultured, and the frequency of apoptotic Jurkat cells and levels of activated caspase-3 were determined by FCM.
Results:
Treatment with CpG-ODN down-regulated the expression of FasL in HepG2 cells in a dose- and time-dependent manner. In addition, treatment with CpG-ODN down-regulated the Fas mRNA transcription and protein expression in Jurkat cells. Treatment of HepG2 cells or Jurkat cells with FasL-neutralizing antibody NOK-2 remarkably inhibited the HepG2-medaited Jurkat cell apoptosis. Pre-treatment of HepG2 or Jurkat cells with CpG-ODN significantly reduced the frequency of HepG2-mediated apoptotic Jurkat cells and inhibited the activation of caspase-3 in Jurkat cells in vitro.
Conclusions:
Our data indicated that treatment with CpG-ODN inhibited the HepG2 cells-mediated Jurkat cell apoptosis by modulating the Fas/FasL pathway. Apparently, CpG-ODN treatment may be a potential therapeutic reagent for HCC.
Insights
CpG oligonucleotides (CpG-ODN) inhibit liver cancer cell-mediated apoptosis by downregulating FasL and Fas expression. This suggests CpG-ODN may be a potential therapeutic for hepatocellular carcinoma (HCC).
Area of Science:
- Immunology
- Hepatology
- Molecular Biology
Background:
- CpG motif-containing oligonucleotides (CpG-ODN) are known immune modulators.
- The Fas/FasL pathway plays a critical role in apoptosis.
- Hepatocellular carcinoma (HCC) involves complex cellular interactions and apoptosis resistance.
Purpose of the Study:
- To investigate the effect of CpG-ODN on FasL expression in HepG2 cells and Fas expression in Jurkat cells.
- To determine if CpG-ODN modulates HepG2 cell-mediated apoptosis of Jurkat cells in vitro.
- To explore the potential of CpG-ODN as a therapeutic agent for HCC.
Main Methods:
- Real-time PCR and flow cytometry (FCM) were used to assess FasL and Fas expression.
- HepG2 and Jurkat cells were co-cultured to evaluate apoptosis.
- FCM was employed to quantify apoptotic Jurkat cells and activated caspase-3 levels.
Main Results:
- CpG-ODN dose- and time-dependently downregulated FasL in HepG2 cells.
- CpG-ODN reduced Fas mRNA and protein expression in Jurkat cells.
- CpG-ODN treatment significantly decreased HepG2-mediated Jurkat cell apoptosis and caspase-3 activation.
Conclusions:
- CpG-ODN inhibits HepG2 cell-mediated Jurkat cell apoptosis via modulation of the Fas/FasL pathway.
- CpG-ODN demonstrates potential as a therapeutic reagent for hepatocellular carcinoma (HCC).
- Targeting the Fas/FasL pathway with CpG-ODN offers a novel strategy for HCC treatment.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
Inhibitors of Viral Protein Synthesis

